

rs199508964 Deletion in exon 6 of IRF5 gene is correlated with IL28B gene SNP rs12980275 and predicts sustained virological response in patients with recurrent hepatitis C following liver transplantation

Deletia rs199508964 din exonul 6 al genei IRF5 se coreleaza cu polimorfismul genei IL28B rs12980275 si prezicera raspunsul virologic sustinut la pacientii cu hepatita recurenta C post-transplant hepatic

Speranta Iacob, Razvan Iacob, Codruta Vagu, Simona Ruta, Cristian Gheorghe, Liliana Paslaru, Irinel Popescu and Liana Gheorghe

Institutul Clinic Fundeni, Bucuresti, Romania

Background: In patients with recurrent HCV infection after liver transplantation (LT), analyses of single nucleotide polymorphisms of IL28B in recipient and donor tissues allows prediction of sustained virological response (SVR) to PEG-Interferon and ribavirin therapy. IRF-5, a member of Interferon Regulatory Factors, a transcription factor, functions as a key regulator in TLR4 cascade, and is capable of inducing inflammatory cytokines. IRF1 and IRF5 have antiviral roles that are IFN-independent and cell-type specific.

Aim: To investigate IL28B polymorphism and IRF5 mutations in Romanian LT recipients with recurrent hepatitis C in order to establish a possible functional explanation for the already proven association of IL28B gene polymorphism to SVR following double antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

Methods: Forty-five LT recipient DNA samples were screened for rs12980275 single nucleotide polymorphism near the IL28B gene and for rs199508964 deletion of 30 bases in IRF5- exon 6, using Sanger sequencing technique.

Results: There were analyzed 23 females and 22 males with a mean age of 52.5 ± 6.9 years and a mean time since LT of 16.3 ± 11.6 months. In our study group no other mutations than rs199508964 were identified in exon 6 of IRF5 gene. IRF genotypes were: wild type (WT) – 14%, heterozygous for the deletion – 44.2%, and homozygous for the deletion – 41.9%. Minor allele frequency (MAF) for rs199508964 in our study group was 64%, higher than - MAF according to Pubmed (48.4%). Distribution of IL28B genotypes were: C/C – 14%, C/T - 58.1%, T/T - 27.9%. There was an association between IRF5- non-WT and IL28B non-C/C genotypes ($p=0.01$). A significant association was found between SVR and WT genotype of IRF5 ($p=0.01$), however mutations in IRF5 gene were not associated to advanced fibrosis after LT.

Conclusions: There is a link between recipient IL28B and IRF5 genotypes that could explain correlation to SVR following double antiviral therapy.